Compare Robinhood Markets, Inc. (HOOD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Robinhood Markets, Inc. trades at $101.78 (market cap $89.13B), while Vertex Pharmaceuticals Incorporated trades at $480 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals.
| HOOD | VRTX | |
|---|---|---|
Market Cap | $89.13B | $121.95B |
Sector | Technology | Health |
52-Week High | $152.46 | $529.59 |
52-Week Low | $65.16 | $366.54 |
Enterprise Value | $90.33B | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood Markets (HOOD) trades at $99.41, down 0.55% on the day, with technical indicators showing a bearish short-term trend. The stock has strong fundamentals, including 2025 revenue of $4.47 billion and net income of $1.88 billion, with a net margin of 42.09%. Recent news highlights institutional selling and CFO share disposals, but analyst consensus remains bullish with a $113.21 price target. Cash flow improved significantly in 2025 to $1.20 billion net.
The outlook for HOOD is mixed: strong profitability and growth support upside potential, but near-term technical weakness and insider selling pose risks. Investors should weigh robust financials against market sentiment and competitive pressures in the fintech sector.
Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.
The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
